Abzena PLC Notice of half year results (2387P)
15 November 2016 - 11:42PM
UK Regulatory
TIDMABZA
RNS Number : 2387P
Abzena PLC
15 November 2016
Abzena plc
Notice of half year results
Cambridge, UK, 15 November 2016 - Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), a life sciences group providing services
and technologies enabling the development and manufacture of
biopharmaceutical products, will be publishing its half year
results for the six months to 30 September 2016 on Wednesday, 30
November 2016.
A presentation for analysts will be held at 9.30am on 30
November 2016 at the offices of Instinctif Partners, 65 Gresham
Street, London EC2V 7NQ.
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / Paul Gillam +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie-Toyne Sewell / Rozi abzena@instinctif.com
Morris
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic
proteins, and cell line development for manufacture.
-- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for
optimizing the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture
ADCs to GMP standards.
For more information, please see www.abzena.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDMMMMZKGGVZM
(END) Dow Jones Newswires
November 15, 2016 07:42 ET (12:42 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024